“J’accuse…!” (French pronunciation: [ʒaˈkyz], “I accuse…!”) was an open letter published on 13 January 1898 in the newspaper L’Aurore by the influential writer Émile Zola.
In the letter, Zola addressed President of France Félix Faure and accused the government of anti-Semitism and the unlawful jailing of Alfred Dreyfus, a French Army General Staff officer who was sentenced to lifelong penal servitude for espionage. Zola pointed out judicial errors and lack of serious evidence. The letter was printed on the front page of the newspaper and caused a stir in France and abroad. Zola was prosecuted for libel and found guilty on 23 February 1898. To avoid imprisonment, he fled to England, returning home in June 1899.
Other pamphlets proclaiming Dreyfus’s innocence include Bernard Lazare’s A Miscarriage of Justice: The Truth about the Dreyfus Affair (November 1896). As a result of the popularity of the letter, even in the English-speaking world, J’accuse! has become a common generic expression of outrage and accusation against someone powerful.
>>>>
referring to post http://ningbolife.com/blog/supportanfrage-anmd-ger-brennan-von-msd-ireland/
“J’accuse…!”
My letter to the CEO of the Pharma company in Ireland, MSD plant in Swords, Dublin, that is manufacturing the PD1 is still unanswered. I get the feeling that profits are of more concern than the supporting to save an individual life. It is really a coward attitude of such “big business leaders“. Hoping and waiting for the problem will solve itself. You have blood on your hands with this attitude. You are deciding about death and life. As you are not god it means you have chosen to be a killer by refusing help which could be easily given by you as a corporate with responsibility. But the only possibility which is shown is toward shareholders and their dividends.
<<<<<<<<<<<
MSD plant in Swords, Dublin
see the sales promotion for MERCK MDS stocks
Merck & Co., Inc. MRK announced that its supplemental Biologics License Application (sBLA) looking to get overall survival data from the phase III KEYNOTE-189 study included on the label of Keytruda was granted approval by the FDA.
The study evaluated Merck’s PD-L1 inhibitor Keytruda in combination with Eli Lilly’s LLY Alimta (pemetrexed) and platinum chemotherapy (cisplatin or carboplatin) for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression.
Data presented from the study in the past had shown that the combination treatment improved overall survival regardless of PD-L1 expression including in patients whose tumors tested negative for PD-L1. The combination significantly improved overall survival, reducing the risk of death by half (51%) compared to chemotherapy alone. Meanwhile, significant improvement in progression-free survival (PFS) was observed, with a reduction in the risk of progression or death of nearly half (48%) for patients in the Keytruda combination arm compared to chemotherapy alone.
Notably, in May 2017, this combination therapy was granted an accelerated approval by the FDA for the aforementioned indication. The approval was based on tumor response rate and PFS data from the phase II KEYNOTE-021 study. The positive readouts from the KEYNOTE-189 confirmatory study helped the company get the accelerated approval converted to a continued approval for the combo therapy, further reinforcing its position in the lung cancer market.
So far this year, Merck’s shares have outperformed the industry, rising 24.7% compared with a 4.8% increase for the industry.
Keytruda is a key contributor to Merck’s sales growth. In a very short span of time, Keytruda has become Merck’s largest product. It is already approved for use in 12 indications across eight different tumor types in the United States.
The treatment generated sales of $1.67 billion in second-quarter 2018, up 13.8% sequentially and 89% year over year. Sales were driven by the launch of new indications globally. Keytruda sales are gaining particularly from strong momentum in the first-line lung cancer indication as it is the only anti-PD-1 approved in first-line setting.
Keytruda development program is also progressing well and is being studied for more than 30 types of cancer in more than 800 studies, including more than 400 combination studies. Merck is collaborating with several companies including Amgen AMGN, Incyte INCY, Glaxo and Pfizer separately for the evaluation of Keytruda in combination with other regimens. These include several lung cancer studies across multiple settings and stages of the disease, both as a monotherapy as well as a combination therapy.
Several regulatory decisions for new indications in the United States as well as in Europe are pending in the second half of 2018 and 2019, which if approved can further boost sales. A key decision on the label expansion of Keytruda as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), which is a difficult-to-treat lung cancer patient population, based on data from the phase 3 KEYNOTE-407 study is due in October.
Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Please share in your media and help to raise the funds required to rescue a life. Maybe even MERCK can understand that human beings are not only production capital made for creating profits. What better advertisement for a company than saving a life.. isn’t it.
